Parthenium dermatitis treated with azathioprine weekly pulse doses [4]

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 3, 2006, Pages 234-

  Srinivas, C ^a  

^a PSG HOSPITALS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; OXIDOREDUCTASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; XANTHIUM OXIDASE;

DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PULSE THERAPY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; LETTER; LOW DRUG DOSE; PANCYTOPENIA; PARTHENIUM DERMATITIS; RISK ASSESSMENT; SKIN INFLAMMATION;

EID: 33745174880     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.25791     Document Type: Letter

References (6)

1. Srinivas CR, Balachandran C, Shenoi SD, Acharya S. Azathioprine in the treatment of parthenium dermatitis. Br J Dermatol 1991;124:394-5.
2. Verma KK, Bansal A, Sethuraman G. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol 2006;72:24-7.
3. Badalamenti S, Kerdel AF. Azathioprine. In: Comprehensive Dermatologic Drug Therapy. Wolverton SE, editor. W. B. Saunders Co: Philadelphia; 2001. p. 165-79.
4. Korman NJ. Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid. Med Surg Dermatol 1996;3:209-13.
5. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
6. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995;32:114-6.